Long-Term Cardiovascular Adverse Events in Patients with Chronic Myelogenous Leukemia Treated with Tyrosine Kinase Inhibitors
BACKGROUND: patients with chronic myelogenous leukemia (CML) treated with tyrosine kinase inhibitors (TKIs) are at risk for cardiotoxicity. Risk estimates from clinical trials may be limited by healthier populations and short follow-up durations. MATERIALS AND METHODS: we evaluated the incidence of cardiovascular adverse events (CVD-AE) and echocardiographic changes as a secondary outcome in CML patients on TKIs, accounting for cardiovascular risk from prior TKI exposure. CML patients treated with TKIs at Cleveland Clinic (2007-2022) were included. TKIs analyzed were imatinib, dasatinib, nilotinib, bosutinib, ponatinib, and asciminib. Data included demographics, comorbidities, treatments, and follow-up. Outcomes were overall survival and major adverse cardiovascular events (MACE): acute coronary syndrome (ACS), heart failure, stroke, peripheral arterial disease, and revascularization. Pleural effusions, pericardial effusions and pulmonary hypertension were assessed. Echocardiograms were collected at baseline. Multivariable Cox regression and generalized linear mixed models were applied. RESULTS: among 357 patients (median age 56; 57% male; 85% White), 518 CVD-AE occurred during median follow-up of 7.2 years. Compared with imatinib, nilotinib was associated with increased ACS (HR 3.5, P = 0.02), dasatinib with heart failure (HR 2.5, P = 0.04), and dasatinib, and asciminib with pleural (HRs 3.5, 5.8; P < 0.05) and pericardial effusions (HR 5.1, 21.6; P < 0.05). Dasatinib was associated with lower venous thrombosis (HR 0.1, P = 0.02). MACE incidence did not differ significantly among TKIs. Among 69 patients with serial echocardiograms, ponatinib decreased left ventricular ejection fraction (β = -5.2, P = 0.008) and bosutinib increased global longitudinal strain (β = 3.0, P = 0.037). CONCLUSION: Cardiovascular risks differ among TKIs, and therapy duration influences echocardiographic changes.
Authors
- Rohit Moudgil (ORCID: https://orcid.org/0000-0001-8258-0675)
- Parker Foster (ORCID: https://orcid.org/0000-0002-3228-5691)
- John C. Molina (ORCID: https://orcid.org/0000-0003-3142-516X)
- Hetty E. Carraway (ORCID: https://orcid.org/0000-0001-5241-3614)
- Moaath K. Mustafa Ali (ORCID: https://orcid.org/0000-0003-3289-2333)
- Naveen Rehman
- Diego Ramonfaur (ORCID: https://orcid.org/0000-0003-3884-149X)
- Aaron Thomas Gerds (ORCID: https://orcid.org/0000-0002-3422-1309)
- Aastha Dhakal (ORCID: https://orcid.org/0009-0000-4495-1324)
- Akriti Gupta Jain (ORCID: https://orcid.org/0000-0002-7238-9241)
- Sophia Balderman (ORCID: https://orcid.org/0000-0001-8157-8725)
- Emily Craig Zabor (ORCID: https://orcid.org/0000-0002-1402-4498)
- Hadil Zureigat (ORCID: https://orcid.org/0000-0002-9593-2550)
- Anjali S. Advani (ORCID: https://orcid.org/0000-0003-0015-5902)
- Bryan Berube
- Sudipto Mukherjee (ORCID: https://orcid.org/0000-0002-8325-2603)
- Ali Hassan Mushtaq (ORCID: https://orcid.org/0000-0003-1939-1665)
- Matt E Kalaycio
- Brandon Z. Francis
- Muaz Alsabbagh Alchirazi (ORCID: https://orcid.org/0000-0003-2456-9130)
- Sneha Govande (ORCID: https://orcid.org/0000-0003-4186-6559)
- Yasmine Elghoul
- Ahmed N Mohamed
- Abhay Singh
Institutions
- Cleveland Clinic (US)
- Mayo Clinic (US)
- Cleveland Clinic Lerner College of Medicine (US)
- Mayo Clinic Comprehensive Cancer Center (Minnesota) (US)
Publication Details
- Journal
- The Oncologist
- Published
- 2026-11-18
- DOI
- https://doi.org/10.1093/oncolo/oyag459
- Primary Topic
- Chemotherapy-induced cardiotoxicity and mitigation
- Type
- article
- Field-Weighted Citation Impact
- 0.00